Skip to main content
Latest news
Browse specialties
Breast cancer Genitourinary cancers Lung & thoracic cancers
In focus
Next-generation sequencing: Emerging biomarkers in thyroid and NSCLCs ctDNA and bladder cancer: Current understanding and beyond ROS1 fusion-positive NSCLC NSCLC driver mutations: Discussing the importance of RET, ALK and ROS1 alterations in NSCLC Early-stage NSCLC management: Surgery, targeted treatment and immunotherapy ALK fusion-positive NSCLC: International approaches to management RET fusion-positive NSCLC: Informing on the use of pralsetinib for patients with RET fusion-positive, advanced NSCLC COVID-19 & cancer
Conferences
SABCS 2022 ESMO 2022 2022 ASCO Annual Meeting
About us
Medicine Matters Oncology
EXTENDED SEARCH
Top

03-08-2017 | Hepatocellular carcinoma | Article

Validation of a Simple Scoring System to Predict Sorafenib Effectiveness in Patients with Hepatocellular Carcinoma

Journal: Targeted Oncology

Authors: Giovan Giuseppe Di Costanzo, Andrea Casadei Gardini, Giorgia Marisi, Francesco Giuseppe Foschi, Mario Scartozzi, Rocco Granata, Luca Faloppi, Stefano Cascinu, Nicola Silvestris, Oronzo Brunetti, Vincenzo Ostilio Palmieri, Giorgio Ercolani, Raffaella Tortora

Publisher: Springer International Publishing

Login to get access

Abstract

Background

Sorafenib is recommended for the treatment of advanced-stage hepatocellular carcinoma (HCC). Nonetheless, it is expensive, effective in few patients, and may cause significant adverse effects. Therefore, accurate selection of patients is needed. In a previous study, we constructed a simple scoring system to predict patients’ outcomes based on the occurrence of sorafenib adverse effects.

Objective

The present study aimed to validate this scoring system in a real-life cohort of HCC patients.

Patients and Methods

Clinical records of 279 outpatients treated with sorafenib in eight Italian centers were retrospectively analyzed. Adverse effects considered to calculate the score were skin toxicity, diarrhea, and arterial hypertension, occurring during the first month of therapy. For each adverse effect, 1 point was assigned if present; and 0 points if absent (resulting in a total score between 0 and 3).

Results

Median overall survival (OS) was 10.8 months and median time to progression (TTP) was 5.1 months. At multivariate analysis, performance status, α-fetoprotein (AFP), and Child-Pugh score were independently associated with TTP and OS. A progressive increase of OS and TTP was observed in patients with scores from 0 to 3 (p < 0.001). Six-, 12-, and 24-month survival probabilities were 55.1, 24.5, and 7.9% in score 0 patients, and 100, 80.9, and 46.2% in score 3 patients, respectively. Complete response was observed in one patient (0.4%), partial responses in 41 (15.2%), and stable disease in 117 (43.5%). The disease control rate in patients with scores of 0, 1, 2, and 3 was 34.3, 51.6, 80.9, and 96.3%, respectively (p < 0.001). Complete or partial responses were not observed in score 0 patients.

Conclusions

We have validated a useful scoring system to predict outcomes in sorafenib-treated HCC patients. This score is easy to calculate and suitable for implementation in daily clinical practice.
Literature
1.
Ferlay J, Soerjomataram II, Dikshit R, et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2014;136:E359–86.
2.
Bosch FX, Ribes J, Cleries R, et al. Epidemiology of hepatocellular carcinoma. Clin Liver Dis. 2005;9:191–211.CrossRefPubMed
3.
Goh GB, Chang P, Tan C. Changing epidemiology of hepatocellular carcinoma in Asia. Best Pract Res Clin Gastroenterol. 2015;29:919–28.CrossRefPubMed
4.
Singal AG, El-Serag HB. Hepatocellular carcinoma from epidemiology to prevention: Translating knowledge into practice. Clin Gastroenterol Hepatol. 2015;13:2140–51.
5.
European Association for the Study of the Liver. EASL–EORTC clinical practice guidelines: Management of hepatocellular carcinoma. J Hepatol. 2012;56:908–43.
6.
Bruix J, Sherman M. Management of Hepatocellular Carcinoma: An update. Hepatology. 2011;53:1020–2.
7.
Omata M, Lesmana LA, Tateishi R, et al. Asian Pacific Association for the Study of the liver consensus. Hepatol Int. 2010;4:439–74.
8.
Nishida N, Kitano M, Sakurai T, et al. Molecular mechanism and prediction of sorafenib chemoresistance in human hepatocellular carcinoma. Dig Dis. 2015;33:771–9.CrossRefPubMed
9.
Berretta M, Rinaldi L, Di Benedetto F, et al. Angiogenesis inhibitors for the treatment of hepatocellular carcinoma. Front Pharmacol. 2016;7:428.PubMedPubMedCentral
10.
Cao G, Li X, Qin C, Li J. Prognostic value of VEGF in hepatocellular carcinoma patients treated with Sorafenib: A meta-analysis. Med Sci Monit. 2015;21:3144–51.
11.
Bruix J, Raoul JL, Sherman M, et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial. J Hepatol. 2012;57:821–9.
12.
Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10:25–34.
13.
Lencioni R, Kudo M, Ye SL, et al. GIDEON (global investigation of therapeutic DEcisions in hepatocellular carcinoma and of its treatment with sorafeNib): Second interim analysis. Int J Clin Pract. 2014;68:609–17.
14.
Cheng AL, Guan Z, Chen Z, Tsao CJ, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: Subset analyses of the phase III Sorafenib Asia–Pacific trial. Eur J Cancer. 2012;48:1452–65.
15.
Song T, Zhang W, Wu Q, et al. A single center experience of sorafenib in advanced hepatocellular carcinoma patients: Evaluation of prognostic factors. Eur J Gastroenterol Hepatol. 2011;23:1233–8.
16.
Pinter M, Sieghart W, Hucke F, et al. Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib. Aliment Pharmacol Ther. 2011;34:949–59.CrossRefPubMed
17.
Wörns MA, Koch S, Niederle IM, et al. The impact of patient and tumour baseline characteristics on the overall survival of patients with advanced hepatocellular carcinoma treated with sorafenib. Dig Liver Dis. 2013;45:408–13.CrossRefPubMed
18.
Cho JY, Paik YH, Lim HY, et al. Clinical parameters predictive of outcomes in sorafenib-treated patients with advanced hepatocellular carcinoma. Liver Int. 2013;33:950–7.CrossRefPubMed
19.
Llovet JM, Pena CE, Lathia CD, et al. Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma. Clin Cancer Res. 2012;18:2290–300.CrossRefPubMed
20.
Zhang Z, Zhou X, Shen H, et al. Phosphorylated ERK is a potential predictor of sensitivity to sorafenib when treating hepatocellular carcinoma: Evidence from an in vitro study. BMC Med. 2009;7:41.
21.
Vincenzi B, Santini D, Russo A, et al. Early skin toxicity as a predictive factor for tumor control in hepatocellular carcinoma patients treated with sorafenib. Oncologist. 2010;15:85–92.CrossRefPubMedPubMedCentral
22.
Di Fiore F, Rigal O, Ménager C, Michel P, Pfister C. Severe clinical toxicities are correlated with survival in patients with advanced renal cell carcinoma treated with sunitinib and sorafenib. Br J Cancer. 2011;105:1811–3.CrossRefPubMedPubMedCentral
23.
Di Costanzo GG, De Stefano G, Tortora R, et al. Sorafenib off-target effects predict outcomes in patients treated for hepatocellular carcinoma. Future Oncol. 2015;11:943–51.CrossRefPubMed
24.
Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30:52–60.CrossRefPubMed
25.
Zhang X, Yang XR, Huang XW, Wang WM, Shi RY, et al. Sorafenib in treatment of patients with advanced hepatocellular carcinoma: A systematic review. Hepatobiliary Pancreat Dis Int. 2012;11:458–66.
26.
Wang Z, Wu XL, Zeng WZ, Xu GS, Xu H, et al. Meta-analysis of the efficacy of sorafenib for hepatocellular carcinoma. Asian Pac J Cancer Prev. 2013;14:691–4.CrossRefPubMed
27.
Peng S, Zhao Y, Xu F, Jia C, Xu Y, et al. An updated meta-analysis of randomized controlled trials assessing the effect of sorafenib in advanced hepatocellular carcinoma. PLoS One. 2014;9:e112530.CrossRefPubMedPubMedCentral
28.
Shao YY, Shau WY, Chan SY, Lu LC, Hsu CH, Cheng AL. Treatment efficacy differences of sorafenib for advanced hepatocellular carcinoma: A meta-analysis of randomized clinical trials. Oncology. 2015;88:345–52.
29.
Zhu AX, Kang YK, Rosmorduc O, Evans TJ, Santoro A, Ross P, et al. Biomarker analyses of clinical outcomes in patients with advanced hepatocellular carcinoma treated with sorafenib with or without erlotinib in the SEARCH trial. Clin Cancer Res. 2016;22:4870–9.CrossRefPubMed
30.
Takeda H, Nishikawa H, Osaki Y, Tsuchiya K, Joko K, Japanese Red Cross Liver Study Group, et al. Proposal of Japan red cross score for sorafenib therapy in hepatocellular carcinoma. Hepatol Res. 2015;45(10):E130–40.
31.
Chu D, Lacouture ME, Fillos T, Wu S. Risk of hand-foot skin reaction with sorafenib: A systematic review and meta-analysis. Acta Oncol. 2008;47:176–86.
32.
Zhang L, Zhou Q, Ma L, Wu Z, Wang Y. Meta-analysis of dermatological toxicities associated with sorafenib. Clin Exp Dermatol. 2011;36:344–50.CrossRefPubMed
33.
Yada M, Masumoto A, Motomura K, Tajiri H, Morita Y, Suzuki H. Indicators of sorafenib efficacy in patients with advanced hepatocellular carcinoma. World J Gastroenterol. 2014;20:12581–7.CrossRefPubMedPubMedCentral
34.
Shomura M, Kagawa T, Shiraishi K, Hirose S, Arase Y, Koizumi J, et al. Skin toxicity predicts efficacy to sorafenib in patients with advanced hepatocellular carcinoma. World J Hepatol. 2014;6:670–6.CrossRefPubMedPubMedCentral
35.
Otsuka T, Eguchi Y, Kawazoe S, Yanagita K, Ario K, Kitahara K. Skin toxicities and survival in advanced hepatocellular carcinoma patients treated with sorafenib. Hepatol Res. 2012;42:879–86.CrossRefPubMed
36.
Reig M, Torres F, Rodriguez-Lope C, Forner A, LLarch N, Rimola J, et al. Early dermatologic adverse events predict better outcome in HCC patients treated with sorafenib. J Hepatol. 2014;61:318–24.CrossRefPubMed
37.
Li Y, Li S, Zhu Y, Liang X, Meng H, Chen J, et al. Incidence and risk of sorafenib-induced hypertension: A systematic review and meta-analysis. J Clin Hypertens. 2014;16:177–85.
38.
Funakoshi T, Latif A, Galsky MD. Risk of hypertension in cancer patients treated with sorafenib: An updated systematic review and meta-analysis. J Hum Hypertens. 2013;27:601–11.
39.
Hamnvik O, Choueiri T, Turchin A, et al. Clinical risk factors for the development of hypertension in patients treated with inhibitors of the VEGF signaling pathway. Cancer. 2015;121:311–9.CrossRefPubMed
40.
Estfan B, Byrne M, Kim R. Sorafenib in advanced hepatocellular carcinoma: Hypertension as a potential surrogate marker for efficacy. Am J Clin Oncol. 2013;36:319–24.
41.
Akutsu N, Sasaki S, Takagi H, et al. Development of hypertension within 2 weeks of initiation of sorafenib for advanced hepatocellular carcinoma is a predictor of efficacy. Int J Clin Oncol. 2015;20:105–10.CrossRefPubMed
42.
Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378–90.CrossRefPubMed
43.
Sica DA. Angiogenesis inhibitors and hypertension: An emerging issue. J Clin Oncol. 2006;24:1329–31.
44.
Levy BI. Blood pressure as a potential biomarker of the efficacy angiogenesis inhibitor. Ann Oncol. 2009;20:200–3.CrossRefPubMed
45.
Scartozzi M, Galizia E, Chiorrini S, et al. Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab. Ann Oncol. 2009;20:227–30.CrossRefPubMed
46.
Rudin CM, Liu W, Desai A, et al. Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity. J Clin Oncol. 2008;26:1119–27.CrossRefPubMedPubMedCentral
47.
Koschny R, Gotthardt D, Koehler C, et al. Diarrhea is a positive outcome predictor for sorafenib treatment of advanced hepatocellular carcinoma. Oncology. 2013;84:6–13.CrossRefPubMed
48.
Bettinger D, Schultheiß M, Knuppel E, et al. Diarrhoea predicts a positive response to sorafenib in patients with advanced hepatocellular carcinoma. Hepatology. 2012;56:789.CrossRefPubMed
49.
Doyle A, Marsh P, Gill R, Rodov M, Mohsen W, Varma P, et al. Sorafenib in the treatment of hepatocellular carcinoma: A multi-centre real-world study. Scand J Gastroenterol. 2016;51:979–85.